Guideline for the Management of Systemic Anti-Cancer Treatment (SACT) Hypersensitivity (NICaN)Submitted by amccune on Thu, 2016-02-25 22:55
Many systemic anti-cancer treatments can cause hypersensitivity reactions. Anaphylaxis is the most severe form of hypersensitivity and is a rapid and often life threatening reaction that may be precipitated by many commonly used SACT drugs. A consistent approach across the Network to the management of these is required and provided within this guidance. This guidance is for all healthcare professionals involved in the delivery of SACT to enable initial recognition and management.